Company Information
Ask for more detail from the seller
Contact Supplierperjeta is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with her2-positive metastatic breast cancer who have not received prior anti-her2 therapy or chemotherapy for metastatic disease [see dosage and administration and clinical studies].